Skip to main content
. 2012 Dec 18;1(12):e62. doi: 10.1038/mtna.2012.54

Figure 1.

Figure 1

Single intramuscular injection of Vivo-PMO-mstn in C57BL10 mice increases muscle mass. Vivo-PMO-mstn (10 µg) was injected into the left tibialis anterior (TA) of C57BL10 mice (n = 6). The contralateral muscle was injected with excipient. Mice were killed after 1, 2, 4, and 8 weeks. (a) Representative products of nested RT-PCR analysis of myostatin exon 2 skipping in treated and control muscles at 1, 2, 4 or 8 weeks after the injection are shown. (b) Densitometric analyses of nested RT-PCR products of myostatin exon 2 skipping in treated and control muscles at 1, 2, 4 or 8 weeks (n = 6). Levels of exon skipping declined 8 weeks after the injection. Both bands corresponding to skipped products were included in the analysis. (c) Change in TA muscle mass following a single intramuscular injection of Vivo-PMO-mstn after 1, 2, 4 or 8 weeks. (Two-tailed t-test, *P = 0.0404; **P = 0.005, n = 6). (d) Representative TA muscles collected 8 weeks after a single injection of saline (left) or Vivo-PMO-mstn (right). Proximal (prox), central (central), and distal (dist) levels of the muscles are indicated by yellow lines. ns, not significant; PMO, phosphorodiamidate morpholino oligomer; RT-PCR, reverse transcription-PCR.